Nationwide Recall Issued for ADHD Medication Due to Reduced Effectiveness
A nationwide recall has been issued for a widely used ADHD medication, lisdexamfetamine dimesylate capsules, a generic version of Vyvanse. This recall is due to concerns about reduced effectiveness. The U.S. Food and Drug Administration (FDA) announced the recall on October 28, 2023.
Reasons for the Recall
The recall was initiated after the medication failed dissolution tests. According to the Board of Pharmacy, dissolution is crucial for drug absorption in the body. If the medication is not in solution, it cannot provide the intended therapeutic effects.
Safety Considerations
Despite the decreased efficacy, officials have stated that taking the recalled medication does not pose any safety or health risks to patients. However, the affected capsules might not deliver the optimal dosage needed for managing ADHD symptoms.
Affected Products
The recall encompasses several dosage strengths of lisdexamfetamine dimesylate capsules, specifically:
- 10 mg
- 20 mg
- 30 mg
- 40 mg
- 50 mg
- 60 mg
- 70 mg
Manufacturing and Distribution Details
Sun Pharmaceutical Industries, Inc. distributed the recalled medication from May 1, 2023, to November 13, 2023. The expiration date for these products is set for 2026.
Next Steps for Patients
Patients who possess the recalled medication are advised to consult their healthcare provider or local pharmacy. They can seek information on obtaining replacements or refunds to ensure they receive effective treatment for their condition.
